Key facts
- It has raised $31.8M; the latest was Later Stage VC ($11.4M) in Aug 2024.
- Notable investors include Enterprise Ireland, MedTech Innovator, European Commission, Bank of Ireland Group, Claret Capital — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for AltraTech
- ·The full record, as it builds
Funding rounds
No funding rounds for AltraTech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About AltraTech
Developer of a viral deoxyribonucleic and ribonucleic acid detection device designed to enhance molecular tools. The company's device uses advanced enrichment and semiconductor techniques to achieve the sensitivity and specificity of PCR methods, in a small portable size, enabling physicians to rapidly and accurately measure and quantify viral RNA, DNA, antigen, or antibody samples and avail an accurate diagnosis.
- Sector
- Healthcare
- HQ
- Cork, Ireland
- Founded
- 2013
- Employees
- 17
- Website
- altratech.com/
- Ownership
- Privately Held (backing)
AltraTech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AltraTech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AltraTech in its N-PORT filings yet. We sweep new filings monthly.